Telix Pharmaceuticals (ASX:TLX) in Focus After Positive U.S. Regulatory Update
Highlights
• Telix Pharmaceuticals shares rose 0.41% to AUD 17.09 during the morning session on 2 July 2026 following a favourable FDA update.
• The U.S. FDA aligned with Telix on progressing Part 2 of the ProstACT Global Phase 3 study for TLX591-Tx.
• Part 2 targets approximately 490 patients globally, with recruitment already underway across multiple countries.
• FDA agreed with the clinical protocol, statistical framework and ongoing safety monitoring plan for the study.
• The company continues expanding its late-stage oncology pipeline alongside its commercial radiopharmaceutical business.
Telix Pharmaceuticals Ltd (ASX:TLX) shares traded 0.41% higher at AUD 17.09 during the morning session on 2 July 2026 after the company announced a favourable regulatory update from the U.S. Food and Drug Administration (FDA) regarding its pivotal ProstACT Global Phase 3 clinical program. While the stock recorded a modest gain following the announcement, it remains approximately 30.95% lower over the past year, reflecting the broader volatility often associated with biotechnology companies progressing late-stage clinical programs.
Telix Pharmaceuticals is a commercial-stage radiopharmaceutical company focused on developing targeted theranostic products designed to diagnose and treat cancer. Its commercial portfolio is anchored by prostate cancer imaging products, including Illuccix®, which is available in 22 countries, and Gozellix®, the company’s next-generation PSMA-PET imaging agent approved by the U.S. FDA. Beyond its marketed products, Telix is advancing several late-stage therapeutic candidates targeting prostate cancer, kidney cancer and recurrent glioblastoma, supported by operations across North America, Europe, Latin America and the Asia-Pacific region.
FDA Supports Advancement of Key Phase 3 Study
The latest announcement centres on TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan), Telix’s investigational therapeutic candidate being evaluated for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Following a Type B meeting with the FDA, the company confirmed that the regulator had completed its review of the Part 1 safety and dosimetry results together with the proposed design for Part 2 of the ProstACT Global Phase 3 trial. According to Telix, the FDA concluded that the safety data generated during the initial stage of the study is sufficient to support progression into Part 2 within the United States.
The outcome represents an important regulatory milestone because it provides alignment between the company and the FDA on how the next stage of the trial should proceed, while maintaining consistency with the broader international study already underway.
Agreement Reached on Clinical Trial Framework
In addition to supporting progression into the next stage of the study, the FDA also agreed with several important elements of the Phase 3 trial design.
According to the company, the regulator aligned with Telix on the Part 2 clinical protocol, the proposed statistical analysis framework and the ongoing safety monitoring plan. These agreements establish a consistent approach for conducting the study as patient recruitment continues internationally and expands into the United States, subject to further regulatory clearance.
Part 2 of ProstACT Global will evaluate TLX591-Tx administered as two doses delivered 14 days apart. The investigational therapy will be combined with one of three established standard-of-care treatment options, consisting of abiraterone, enzalutamide or docetaxel. Patients will be randomly assigned across these treatment combinations as part of the study design.
The company noted that the regulatory alignment provides a common framework for execution across participating regions as the global study continues to expand.
Part 2 Recruitment Continues Across Multiple Countries
Although U.S. initiation remains subject to regulatory review of an Investigational New Drug (IND) amendment, patient recruitment for Part 2 is already progressing in several jurisdictions where approvals have been received.
Currently, recruitment is underway in Australia, New Zealand, Canada, Türkiye and the United Kingdom. Regulatory approvals have also been granted for the study to commence in China, Singapore and South Korea.
Telix indicated that the forthcoming IND amendment submitted to the FDA will also be aligned with a pending regulatory submission intended to initiate the ProstACT Global study across Europe.
According to the company, enrolment in regions where recruitment is currently open continues to progress while preparations for broader geographic expansion remain ongoing.
Large International Trial Targets Approximately 490 Patients
ProstACT Global is structured as an international multicentre Phase 3 study conducted in two stages.
Part 1 served as a safety and dosimetry lead-in involving 36 patients and has now been completed. Building on those results, the study has advanced toward the larger global expansion phase.
Part 2 has an overall target enrolment of approximately 490 patients and follows a 2:1 randomised study design.
Eligible participants are patients with confirmed progressive metastatic castration-resistant prostate cancer whose disease has been assessed using a ^68Ga-PSMA-11 PET imaging agent, including products such as Illuccix® or Gozellix®, following previous treatment with one androgen receptor pathway inhibitor (ARPI).
The study is intended to evaluate the therapeutic candidate within a broader standard-of-care treatment setting while gathering efficacy and safety data across multiple international clinical centres.
Therapeutic Approach Designed to Address Treatment Challenges
Telix highlighted several characteristics of TLX591-Tx that differentiate it from currently available PSMA-targeted small molecule radioligand therapies.
The company stated that its antibody-based therapeutic approach offers distinct targeting characteristics and pharmacological behaviour.
Based on long-term follow-up of patients who have previously received TLX591-Tx, the company reported that significant acute or delayed kidney toxicity has not been observed. Telix attributes this to the therapy being primarily excreted through the liver rather than the kidneys, with the liver being comparatively more resistant to radiation exposure.
The company also noted that TLX591-Tx has demonstrated minimal uptake in the salivary and lacrimal glands. According to Telix, this may reduce the occurrence of dry mouth (xerostomia) and dry eye, which are commonly reported side effects associated with existing PSMA-targeted radioligand therapies.
These observations form part of the rationale supporting continued evaluation of the therapy within the ongoing Phase 3 program.
Management Highlights Regulatory Progress
Commenting on the regulatory outcome, Group Chief Medical Officer Dr David N. Cade said the FDA meeting represented an encouraging result that supports submission of the company’s IND amendment required to initiate Part 2 of ProstACT Global within the United States.
He also noted that recruitment into Part 2 continues to progress in regions where enrolment has already commenced.
Separately, ProstACT Global Principal Investigator and Steering Committee member Professor Neeraj Agarwal said TLX591-Tx has the potential to broaden how radiopharmaceutical therapies may be incorporated into routine clinical practice. He noted that the treatment course is designed to be delivered over approximately two weeks, allowing physicians to integrate the therapy into existing treatment regimens while minimising disruption and preserving future treatment options for patients with metastatic prostate cancer.
Commercial Portfolio Supported by Late-Stage Pipeline
Alongside the advancement of TLX591-Tx, Telix continues to develop a broader oncology portfolio spanning both diagnostic imaging and therapeutic applications.
The company’s commercial business is centred on its prostate cancer imaging franchise, with Illuccix® currently marketed across 22 countries. It also recently expanded its imaging portfolio through Gozellix®, its next-generation PSMA-PET imaging agent that has received FDA approval in the United States.
Beyond prostate cancer, Telix’s late-stage development pipeline includes TLX101-Tx for recurrent glioblastoma and TLX250-Tx for kidney cancer, both of which are progressing through pivotal-stage clinical trials.
This combination of commercial products and advanced development programs forms the foundation of the company’s broader strategy within precision oncology and radiopharmaceutical therapies.
What This Means for Investors
The latest update represents a regulatory milestone for Telix’s lead therapeutic program rather than a commercial approval. The FDA’s agreement that Part 1 safety data is sufficient to support progression into the U.S. component of Part 2, together with alignment on the clinical protocol, statistical analysis plan and safety monitoring framework, provides greater clarity for the ongoing execution of the ProstACT Global Phase 3 study. Recruitment continues across multiple international markets while the company prepares regulatory submissions required to expand the trial into the United States and Europe.
FAQs
